RBC Capital raises Agios price target to $32

0 min read Updated on 08 Jul 2026, 12:57 AM

Reviewed by

Radhika SScanX News Team

AI Summary

RBC Capital analyst Luca Issi maintained a Sector Perform rating on Agios Pharmaceuticals (NASDAQ: AGIO) and raised the price target to $32 from $28, following a review of the company's operational performance and market position.

*this image is generated using AI for illustrative purposes only.

RBC Capital analyst Luca Issi has maintained a Sector Perform rating on Agios Pharmaceuticals (NASDAQ: AGIO) and raised the price target to $32 from $28. This adjustment follows a review of the company's operational performance and market position. The revised target indicates a revised outlook for the stock while retaining a neutral investment stance.

Rating and Price Action

The decision to uphold the Sector Perform rating reflects RBC Capital's cautious view on Agios Pharmaceuticals. The new price target of $32 represents an increase from the previous target of $28, suggesting a shift in valuation expectations.

Metric	Value
Rating	Sector Perform
Previous Price Target	$28
New Price Target	$32
Exchange	NASDAQ
Ticker	AGIO

What specific operational improvements or market factors drove RBC Capital to raise the price target while maintaining a neutral rating?

How might Agios Pharmaceuticals' upcoming clinical trial results influence future analyst ratings and stock performance?

What are the potential risks or challenges that could prevent Agios from reaching the new $32 price target?

Read Next Article

Agios Pharmaceuticals to announce Q2 2026 results on July 30

1 min read Updated on 29 Jun 2026, 04:59 PM

Reviewed by

Shriram SScanX News Team

Add as a preferred
source on Google

AI Summary

Agios Pharmaceuticals will announce its Q2 2026 financial results on July 30, 2026, via a conference call and webcast. The event begins at 8:00 a.m. ET, with a replay available later that day.

*this image is generated using AI for illustrative purposes only.

Agios Pharmaceuticals, Inc. will announce its second quarter 2026 financial results and business highlights during a conference call and live webcast on July 30, 2026, at 8:00 a.m. ET. The announcement will provide investors with an update on the company's performance and strategic developments for the quarter.

The live webcast can be accessed through the Investors section of the Agios Pharmaceuticals website under the "Events & Presentations" tab. For those unable to attend the live event, a replay will be available on the website approximately two hours after the conclusion of the call.

Agios Pharmaceuticals is a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases. The company is headquartered in Cambridge, Massachusetts.

Key Event Details

Event Detail	Information
Event Type	Q2 2026 Financial Results Conference Call and Webcast
Date	July 30, 2026
Time	8:00 a.m. ET
Webcast Location	Investors section of www.agios.com
Replay Availability	Approximately two hours after the event

The company utilizes its website as a primary channel for disseminating material information, including press releases, SEC filings, and public conference calls. Investors can sign up for email alerts regarding upcoming events and presentations through the "IR Resources" tab on the website.

What strategic milestones or clinical trial readouts does Agios anticipate highlighting for the remainder of 2026?

How might the Q2 financial results influence Agios's investment in R&D for rare disease treatments?

Will the conference call provide updates on potential partnerships or acquisitions to expand their rare disease portfolio?